Why Molson Coors Beverage Shares Are Falling Today

Molson Coors Beverage Co (NYSE: TAP) reported 

Molson Coors Beverage Co (NYSE:TAP) reported second-quarter FY23 sales growth of 11.8% year-on-year to $3.27 billion, missing the analyst consensus of $3.29 billion.

The sales increase was primarily due to positive net pricing, favorable sales mix, and higher financial volumes.

Net sales from the Americas segment increased 10.7% reported, and 11.5% in constant currency.

Net sales from EMEA & APAC segment jumped 16.3%, driven by favorable price and sales mix and favorable foreign currency impacts, partially offset by a decline in financial volumes.

Underlying cost of goods sold (COGS) per hectoliter increased 5.9% in constant currency.

Gross profit climbed 48.6% Y/Y to $1.218 billion. Operating income for the quarter was $488.5 million, with a margin of 12.8%.

Molson Coors Beverage held $960.9 million in cash and equivalents as of June 30, 2023. Cash provided by operating activities for six months totaled $894.4 million.

Underlying EBITDA for the quarter gained 28% to $725.2 million.

Non-GAAP EPS of $1.78 beat the consensus of $1.59.

Outlook: Molson Coors sees FY23 net sales growth in high single-digit versus 2022 on a constant currency basis from the previous guidance of a low single-digit increase.

It expects underlying free cash flow of $1.2 billion, plus or minus 10%, versus previous guidance of $1.0 billion, plus or minus 10%.

Price Action: TAP shares traded lower by 5.39% at $66.01 in premarket on the last check Tuesday.

Total
0
Shares
Related Posts
Read More

Canadian Marijuana Company Cronos Expands Into UK After Setting Up In Germany’s Nascent Market

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) announced on Tuesday that it's expanding its medical brand, PEACE NATURALS, into the United Kingdom market with its first shipment of cannabis flower to GROW Pharma.The Toronto-based cannabis company has partnered with a distributor of prescribed medicinal cannabis products in the UK after years of investing in research and development, tissue culture, and its cannabis genetics breeding program.The debut in the UK follows the company's expansion in Germany and Australia last year, after successfully expanding across Canada and Israel.

CRON